載入...
AMD3100/Plerixafor overcomes immune inhibition by the CXCL12–KRT19 coating on pancreatic and colorectal cancer cells
A recent Phase 1 clinical study of the immunological effects of inhibiting the chemokine receptor, CXCR4, in patients with pancreatic ductal adenocarcinoma or colorectal cancer suggests that stimulation of CXCR4 on immune cells suppresses the intratumoural immune reaction. Here, we discuss how CXCR4...
Na minha lista:
| 發表在: | Br J Cancer |
|---|---|
| Main Authors: | , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Nature Publishing Group UK
2021
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8292464/ https://ncbi.nlm.nih.gov/pubmed/33772153 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-021-01315-y |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|